LORVIQUA® has a generally manageable safety profile with a low discontinuation rate2
Adverse reactions occurring in ≥ 20% of patients treated with LORVIQUA® (N=295)*2
© 2021 Pfizer Pte Ltd. All rights reserved.
The information provided in this site is intended only for Health Care Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Corporation Singapore Limited is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.